Navigation Links
ChromaDex®'s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers
Date:9/8/2011

IRVINE, Calif., Sept. 8, 2011 /PRNewswire/ -- ChromaDex® Corp. (OTCBB: CDXC) today announced that the University of California, Irvine has granted ChromaDex® the exclusive rights to a joint patent application filed by ChromaDex® and the university for the method of inducing UDP-glucuronosyltransferase (UGT) activity using pTeroPure®, ChromaDex®'s ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits. UGT is an enzyme responsible for the process of glucuronidation, which changes unwanted compounds in to a more water-soluble version, thus allowing for easier elimination from the body. It is known that UGTs prevent melanoma invasiveness by eliminating toxic compounds and are subsequently lost during melanoma progression.  

(Logo:  http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

With more than 3.5 million skin cancers diagnosed in more than two million people annually,(1) data shows that there has been at least a 300 percent increase in skin cancer incidence since 1994.(2) Researchers believe that pTeroPure® may show promise for the regression of precancerous diseases such as actinic keratoses (AK) and other changes that are associated with photodamage of the skin. AKs are the earliest identifiable lesions that can eventually develop into skin cancer. These lesions are diagnosed in 14 percent of all visits to dermatologists, following only acne and dermatitis in frequency according to the American Academy of Dermatology.

The pterostilbene-based pTeroPure® may also be used to suppress or prevent progression of these precancerous diseases to non-melanoma skin cancer (NMSC). In prior studies, pterostilbene has been shown to inhibit melanoma cell growth, although the mechanism of action is still being determined.(3)

"As we continue to build on our strategy of increasing intellectual property with our proprietary ingredients, we also strive to provide solutions to increase quality of life," said Frank L. Jaksch, Jr., CEO of ChromaDex®. "Adding this patent to our portfolio reinforces ChromaDex®'s commitment to bringing science-based solutions to the market."

"Our research to evaluate pterostilbene's effectiveness in the prevention and treatment of skin damage and cancers will potentially offer medical professionals and patients alike a new approach in battling the devastating effects of diseases like melanoma and other skin cancers," said Frank Meyskens, MD, Director of the Chao Family Comprehensive Cancer Center, University of California, Irvine.

"For over 11 years, ChromaDex® has been committed to the discovery and development of ingredients that promote health and well-being," said William Spengler, President of ChromaDex®. "We are now uniquely positioned to enter a potentially very large but underserved segment of the skincare market with our novel ingredient pTeroPure®."

About ChromaDex®

ChromaDex® is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights. 

ChromaDex® Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

(1) Rogers, HW, Weinstock, MA, Harris, AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146(3):283-287.

(2) The Skin Cancer Foundation: http://www.skincancer.org/nonmelanoma-skin-cancer-incidence-jumps-by-over-300-percent.html. Accessed August 31, 2011.

(3) Schneider JG, Alosi JA, McDonald DE, McFadden DW. Effects of pterostilbene on melanoma alone and in synergy with inositol hexaphosphate. Am J Surg 2010; 198:679-684.


'/>"/>
SOURCE ChromaDex Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
2. Curemark Reports Positive Results for Novel Compound CM-182 in Amphetamine Induced Hyperactivity
3. Alzheimers Drug Discovery Foundation Supports Madera Biosciences with a Grant to Advance Novel Drug Candidates for Alzheimers Disease
4. KalVista Pharmaceuticals Launched With £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema
5. Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform
6. Kuros Completes Patient Recruitment in its European Clinical Study With KUR-023, its Novel Dural Sealant Product Candidate
7. QIAGEN and Pfizer Partner to Develop Companion Diagnostic for Novel Compound in Global Clinical Trials for Lung Cancer
8. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
9. Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicines Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds
10. Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102
11. Porter Novelli Named Agency of Record for Prix Galien USA Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... Kohll,s Pharmacy & Homecare is the first distributor of ... . The Raizer is a simple battery operated mobile ... an almost-standing position within a few minutes. The ... and does not require any extra effort besides a ... can operate it, and lightweight and portable so ...
(Date:6/1/2017)... BELL, Pa. , June 1, 2017 ... (PRN) and Veterinarian Recommended Solutions (VRS), and KD Pharma ... investment in Nutriceutical Holdings by KD Pharma Group. KD ... Holdings with the option to acquire the entire company. ... partner in KD. They are committed to growing the ...
(Date:5/30/2017)... TEL AVIV, Israel , May 30, 2017 /PRNewswire/ ... clinical stage pharmaceutical Company specializing in the development ... management will present a company overview at three ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... Anyone with a remote control has seen ... can do it, you the flipper will get rich in no time. But what ... wrong things can get for the buyer of a flipped house. An email recently ...
(Date:6/28/2017)... Philadelphia, PA (PRWEB) , ... June 28, 2017 ... ... will host a one-day corporate governance program for mid-market executives as a kick-off ... will be held Sunday, Sept. 24, 2017 on the University of Pennsylvania campus, ...
(Date:6/28/2017)... ... 28, 2017 , ... Canadian Zeolite Corp. (the “Company”) (TSX.V: ... study conducted by the University of Saskatchewan in partnership with PotashCorp, Agrium and ... groundwater. As a part of the study, batch adsorption experiments were conducted with ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... a cosmetic treatment, according to survey data released today by the American ... Cosmetic Dermatologic Procedures indicates the percentage of consumers considering a cosmetic medical ...
Breaking Medicine News(10 mins):